News
HUMA
0.4482
+13.32%
0.0527
Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note
NASDAQ · 1d ago
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates
NASDAQ · 2d ago
Humacyte Announces Three Presentations At American Heart Association Scientific Sessions, November 6–9; Two Additional Presentations To Cover First-In-Human Phase 2a Study Design And Preclinical Results For Its Investigational Coronary Tissue Engineered Vessel
Benzinga · 4d ago
Weekly Report: what happened at HUMA last week (1026-1030)?
Weekly Report · 5d ago
Humacyte issued new U.S. patent covering Symvess
TipRanks · 10/28 12:21
Weekly Report: what happened at HUMA last week (1019-1023)?
Weekly Report · 10/26 10:07
Humacyte's ATEV Shows Phase 3 Benefits In Women, Supports Planned FDA Label Expansion
NASDAQ · 10/23 17:15
Humacyte Presents Interim Results From V012 Phase 3 Clinical Trial Of Acellular Tissue Engineered Vessel In Arteriovenous Access For Female Hemodialysis Patients, At ASN Kidney Week 2026
Benzinga · 10/23 12:03
Weekly Report: what happened at HUMA last week (1012-1016)?
Weekly Report · 10/19 10:07
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 10/16 21:05
Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Healthequity (HQY)
TipRanks · 10/16 10:40
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 10/15 17:05
Humacyte Reports Accelerating Commercial Adoption, Reports 44% Increase In Hospitals Ordering Symvess To 49 In Q3 2026
Benzinga · 10/15 13:18
Humacyte says hospitals ordering Symvess rose 44% in Q3 to 49
TipRanks · 10/15 13:16
Weekly Report: what happened at HUMA last week (1005-1009)?
Weekly Report · 10/12 10:11
Stryker, Abbott among Overweight ideas as Barclays turns bullish on MedTech
Seeking Alpha · 10/07 18:35
Barclays Initiates Coverage of Humacyte at Equal-Weight
NASDAQ · 10/07 18:22
Flutter upgraded, AppFolio downgraded: Wall Street’s top analyst calls
TipRanks · 10/07 14:06
Humacyte Initiated at Equal-Weight by Barclays
Dow Jones · 10/07 12:54
Humacyte Price Target Announced at $0.50/Share by Barclays
Dow Jones · 10/07 12:54
More
Webull provides a variety of real-time HUMA stock news. You can receive the latest news about Humacyte Inc through multiple platforms. This information may help you make smarter investment decisions.
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.